Efficacy and Safety of S-1 Combined with Oxaliplatin as First Line Chemotherapy in Patients with Gastric Cancer

Objective To evaluate the efficacy and safety profile of S-1 combined with oxaliplatin(SOX) for the treatment of locally advanced unresectable or metastatic gastric cancer.Methods Oxaliplatin was given by intravenous drop(130 mg/m2) on the first day,while S-1 was given orally(40 mg/m2,b.i.d.) for 14 days followed by a 7-day rest.This schedule was repeated every 3 weeks.Treatment was continued until disease progressed or intolerable toxicity occurred.Results Sixty-one patients were enrolled,all were assessable for safety and survival.Forty-six patients were objectively assessable for tumor response.The response rate was 56.5%,and the disease control rate was 76.1%.The median progression-free survival time was 7.5 months(95% CI: 5.1-9.7 months),the 1-year survival rate was 62.9%,and the estimated median survival time was 16 months(95% CI:13.2-18.8 months).The major grade 3/4 toxic effects were neutropenia(13.1%) and thrombocytopenia(18%)decreased.Conclusion These findings indicate that SOX regimen is feasible and shows promising efficacy against advanced gastric cancer.